Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 6, 2007, Pages

  Roberge, Claude ^a   Carpentier, André C ^a   Langlois, Marie France ^a   Baillargeon, Jean Patrice ^a   Ardilouze, Jean Luc ^a   Maheux, Pierre ^a,b   Gallo Payet, Nicole ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b PFIZER INC   (United States)

Author keywords

Adipocytes; Adrenal gland; Adrenal steroids; Adrenocorticotropic hormone; Angiotensin II

Indexed keywords

ALDOSTERONE; ANDROGEN; GLUCOCORTICOID; PRASTERONE; PRASTERONE SULFATE;

ADIPOSE TISSUE; ADRENAL CORTEX; ADRENAL CORTEX DISEASE; ADRENAL CORTEX FUNCTION; ENERGY BALANCE; FOOD INTAKE; GLUCOSE METABOLISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN RESISTANCE; LIPID STORAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ONSET AGE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEROID METABOLISM; STEROID RELEASE; STEROIDOGENESIS; ZONA GLOMERULOSA;

EID: 37149023156     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00516.2007     Document Type: Review

References (207)

1. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin- converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46: 821-826, 2005.
2. Aguilera G, Young WS, Kiss A, Bathia A. Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology 61: 437-444, 1995.
3. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 62: 413-437, 2000.
4. Albertin G, Tortorella C, Malendowicz LK, Aragona F, Neri G, Nussdorfer GG. Human adrenal cortex and aldosterone secreting adenomas express both 11beta-hydroxysteroid dehydrogenase type 1 and type 2 genes. Int J Mol Med 9: 495-498, 2002.
5. Almon RR, Dubois DC, Jin JY, Jusko WJ. Temporal profiling of the transcriptional basis for the development of corticosteroid-induced insulin resistance in rat muscle. J Endocrinol 184: 219-232, 2005.
6. Andrew R, Phillips DI, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83: 1806-1809, 1998.
7. Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue. Am J Physiol Endocrinol Metab 288: E957-E964, 2005.
8. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48: 51-57, 2006.
9. Armando I, Carranza A, Nishimura Y, Hoe KL, Barontini M, Terron JA, Falcon-Neri A, Ito T, Juorio AV, Saavedra JM. Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic- pituitary-adrenal response to isolation Stress. Endocrinology 142: 3880-3889, 2001.
10. Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res 1142: 92-99, 2007.
11. Arner P. Catecholamine-induced lipolysis in obesity. Int J Obes Relat Metab Disord 23, Suppl 1: 10-13, 1999.
12. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237: 268-275, 1987.
13. Asensio C, Muzzin P, Rohner-Jeanrenaud F. Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int J Obes Relat Metab Disord 28, Suppl 4: S45-S52, 2004.
14. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91: 4237-4245, 2006.
15. Baillargeon J, Carpentier A. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 88: 886-893, 2007.
16. Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs 6: 1012-1022, 2005.
17. Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 91: 22-24, 2006.
18. Barroso I. Genetics of Type 2 diabetes. Diabet Med 22: 517-535, 2005.
19. Benkirane K, Amiri F, Diep QN, El Mabrouk M, Schiffrin EL. PPARγ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1. Am J Physiol Heart Circ Physiol 290: H390-H397, 2006.
20. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002, 2004.
21. Berthiaume M, Sell H, Lalonde J, Gelinas Y, Tchernof A, Richard D, Deshaies Y. Actions of PPARgamma agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids. Am J Physiol Regul Integr Comp Physiol 287: R1116-R1123, 2004.
22. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 90: 3886-3896, 2005.
23. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2: 73-86, 2001.
24. Bjorntorp P, Rosmond R. Obesity and cortisol. Nutrition 16: 924-936, 2000.
25. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol 26: 28-40, 2006.
26. Blouin K, Blanchette S, Richard C, Dupont P, Luu-The V, Tchernof A. Expression and activity of steroid aldoketoreductases 1C in omental adipose tissue are positive correlates of adiposity in women. Am J Physiol Endocrinol Metab 288: E398-E404, 2005.
27. Blouin K, Richard C, Belanger C, Dupont P, Daris M, Laberge P, Luu-The V, Tchernof A. Local androgen inactivation in abdominal visceral adipose tissue. J Clin Endocrinol Metab 88: 5944-5950, 2003.
28. Blouin K, Richard C, Brochu G, Hould FS, Lebel S, Marceau S, Biron S, Luu-The V, Tchernof A. Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 191: 637-649, 2006.
29. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55: 3053-3060, 2006.
30. Boschmann M, Jordan J, Schmidt S, Adams F, Luft FC, Klaus S. Gender-specific response to interstitial angiotensin II in human white adipose tissue. Horm Metab Res 34: 726-730, 2002.
31. Bruder ED, Ball DL, Goodfriend TL, Raff H. An oxidized metabolite of linoleic acid stimulates corticosterone production by rat adrenal cells. Am J Physiol Regul Integr Comp Physiol 284: R1631-R1635, 2003.
32. Bruder ED, Raff H, Goodfriend TL. An oxidized derivative of linoleic acid stimulates dehydroepiandrosterone production by human adrenal cells. Horm Metab Res 38: 803-806, 2006.
33. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11beta-hydroxysteroid dehydrogenase. Endocrinology 140: 3188-3196, 1999.
34. Cabassi A, Coghi P, Govoni P, Barouhiel E, Speroni E, Cavazzini S, Cantoni AM, Scandroglio R, Fiaccadori E. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab 90: 2888-2897, 2005.
35. Campion J, Maestro B, Molero S, Davila N, Carranza MC, Calle C. Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the downregulation of its own receptor. Cell Biochem Funct 20: 237-245, 2002.
36. Capponi AM. The control by angiotensin II of cholesterol supply for aldosterone biosynthesis. Mol Cell Endocrinol 217: 113-118, 2004.
37. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 21: 2185-2194, 2007.
38. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45: 840-844, 2005.
39. Chappell MC, Diz DI, Jacobsen DW. Pharmacological characterization of angiotensin II binding sites in the canine pancreas. Peptides 13: 313-318, 1992.
40. Charmandari E, Chrousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann NY Acad Sci 1083: 37-53, 2006.
41. Clasen R, Schupp M, Foryst-Ludwig A, Sprang C, Clemenz M, Krikov M, Thone-Reineke C, Unger T, Kintscher U. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 46: 137-143, 2005.
42. Clement K. Genetics of human obesity. Proc Nutr Soc 64: 133-142, 2005.
43. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev 27: 736-749, 2006.
44. Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 5: 106-109, 2003.
45. Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Milgrom E, Schaison G. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab 86: 5060-5066, 2001.
46. Cussons AJ, Stuckey BG, Watts GF. Metabolic syndrome and cardiometabolic risk in PCOS. Curr Diab Rep 7: 66-73, 2007.
47. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368: 581-588, 2006.
48. Dallman MF, la Fleur SE, Pecoraro NC, Gomez F, Houshyar H, Akana SF. Minireview. Glucocorticoids - food intake, abdominal obesity, and wealthy nations in 2004. Endocrinology 145: 2633-2638, 2004.
49. Dallman MF, Pecoraro N, Akana SF, La Fleur SE, Gomez F, Houshyar H, Bell ME, Bhatnagar S, Laugero KD, Manalo S. Chronic stress and obesity: a new view of "comfort food". Proc Natl Acad Sci USA 100: 11696-11701, 2003.
50. Darimont C, Vassaux G, Ailhaud G, Negrel R. Differentiation of preadipose cells: paracrine role of prostacyclin upon stimulation of adipose cells by angiotensin-II. Endocrinology 135: 2030-2036, 1994.
51. de Paula RB, da Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43: 41-47, 2004.
52. DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int J Clin Pract Suppl: 9-21, 2004.
53. Delarue C, Contesse V, Lenglet S, Sicard F, Perraudin V, Lefebvre H, Kodjo M, Leboulenger F, Yon L, Gallo-Payet N, Vaudry H. Role of neurotransmitters and neuropeptides in the regulation of the adrenal cortex. Rev Endocr Metab Disord 2: 253-267, 2001.
54. Desbriere R, Vuaroqueaux V, Achard V, Boullu-Ciocca S, Labuhn M, Dutour A, Grino M. 11Beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients. Obesity (Silver Spring) 14: 794-798, 2006.
55. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444: 881-887, 2006.
56. Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18: 1321-1332, 2004.
57. Dhillo WS, Gardiner JV, Castle L, Bewick GA, Smith KL, Meeran K, Todd JF, Ghatei MA, Bloom SR. Agouti related protein (AgRP) is upregulated in Cushing's syndrome. Exp Clin Endocrinol Diabetes 113: 602-606, 2005.
58. Dhillo WS, Small CJ, Gardiner JV, Bewick GA, Whitworth EJ, Jethwa PH, Seal LJ, Ghatei MA, Hinson JP, Bloom SR. Agouti-related protein has an inhibitory paracrine role in the rat adrenal gland. Biochem Biophys Res Commun 301: 102-107, 2003.
59. Doghman M, Delagrange P, Berthelon MC, Durand P, Naville D, Begeot M. Sustained inhibitory effect of Agouti related protein on the ACTH-induced cortisol production by bovine cultured adrenal cells. Regul Pept 124: 215-219, 2005.
60. Doghman M, Delagrange P, Blondet A, Berthelon MC, Durand P, Naville D, Begeot M. Agouti-related protein antagonizes glucocorticoid production induced through melanocortin 4 receptor activation in bovine adrenal cells: a possible autocrine control. Endocrinology 145: 541-547, 2004.
61. Doghman M, Soltani Y, Rebuffet V, Naville D, Begeot M. Role of Agouti-related protein in adrenal steroidogenesis. Mol Cell Endocrinol 265-266: 108-112, 2007.
62. Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason PJ, Connell JM, Shackleton CH, Stewart PM. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet 34: 434-439, 2003.
63. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774-800, 1997.
64. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 19: 101-143, 1998.
65. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci USA 100: 14211-14216, 2003.
66. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54: 2838-2843, 2005.
67. Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88: 2760-2766, 2003.
68. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M, Mannelli M. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 90: 1332-1339, 2005.
69. Flier JS. The adipocyte: storage depot or node on the energy information superhighway? Cell 80: 15-18, 1995.
70. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116: 337-350, 2004.
71. Frei N, Weissenberger J, Beck-Sickinger AG, Hofliger M, Weis J, Imboden H. Immunocytochemical localization of angiotensin II receptor subtypes and angiotensin II with monoclonal antibodies in the rat adrenal gland. Regul Pept 101: 149-155, 2001.
72. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 280: E827-E847, 2001.
73. Funder JW. Aldosterone action: fact, failure and the future. Clin Exp Pharmacol Physiol Suppl 25: S47-S50, 1998.
74. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61, 1995.
75. Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, Pasquali R, Walker BR. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab 91: 2295-2302, 2006.
76. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, Boscaro M. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25: 177-186, 2007.
77. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16: 120-126, 2005.
78. Godoy-Matos AF, Vieira AR, Moreira RO, Coutinho WF, Carraro LM, Moreira DM, Pasquali R, Meirelles RM. The potential role of increased adrenal volume in the pathophysiology of obesity-related type 2 diabetes. J Endocrinol Invest 29: 159-163, 2006.
79. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab 91: 4085-4091, 2006.
80. Goodfriend TL. Aldosterone - a hormone of cardiovascular adaptation and maladaptation. J Clin Hypertens (Greenwich) 8: 133-139, 2006.
81. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43: 358-363, 2004.
82. Goodfriend TL, Kelley DE, Goodpaster BH, Winters SJ. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res 7: 355-362, 1999.
83. Goossens GH, Blaak EE, Arner P, Saris WH, van Baak MA. Angiotensin II: a hormone that affects lipid metabolism in adipose tissue. Int J Obes (Lond) 31: 382-384, 2007.
84. Goossens GH, Blaak EE, Saris WH, van Baak MA. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 89: 2690-2696, 2004.
85. Graham M, Shutter JR, Sarmiento U, Sarosi I, Stark KL. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 17: 273-274, 1997.
86. Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31: 2591-2599, 2006.
87. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 41: 463-471, 1994.
88. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 440: 944-948, 2006.
89. Hsieh PS, Tai YH, Loh CH, Shih KC, Cheng WT, Chu CH. Functional interaction of AT1 and AT2 receptors in fructose-induced insulin resistance and hypertension in rats. Metabolism 54: 157-164, 2005.
90. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 20: 953-970, 2006.
91. Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 72: 184-190, 2006.
92. Jezova D, Ochedalski T, Kiss A, Aguilera G. Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol 10: 67-72, 1998.
93. Johren O, Golsch C, Dendorfer A, Qadri F, Hauser W, Dominiak P. Differential expression of AT1 receptors in the pituitary and adrenal gland of SHR and WKY. Hypertension 41: 984-990, 2003.
94. Juvet LK, Andresen SM, Schuster GU, Dalen KT, Tobin KA, Hollung K, Haugen F, Jacinto S, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI. On the role of liver X receptors in lipid accumulation in adipocytes. Mol Endocrinol 17: 172-182, 2003.
95. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Tanaka T, Furuta M, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y. Plasma levels of agouti-related protein are increased in obese men. J Clin Endocrinol Metab 86: 1921-1924, 2001.
96. Kempna P, Hofer G, Mullis PE, Fluck CE. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol Pharmacol 71: 787-798, 2007.
97. Kintscher U, Lyon CJ, Law RE. Angiotensin II, PPAR-gamma and atherosclerosis. Front Biosci 9: 359-369, 2004.
98. Kitamura T, Feng Y, Kitamura YI, Chua SC Jr, Xu AW, Barsh GS, Rossetti L, Accili D. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat Med 12: 534-540, 2006.
99. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355-7359, 1994.
100. Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M, Chiwata T, Miyamoto Y, Yoshimasa Y, Fukamizu A, Horiuchi M, Hirata Y, Ogawa Y. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 146: 3481-3489, 2005.
101. Krysiak R, Okopien B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep 58: 614-625, 2006.
102. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843-850, 2006.
103. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann NY Acad Sci 1083: 77-110, 2006.
104. Kyrou I, Valsamakis G, Tsigos C. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann NY Acad Sci 1083: 270-305, 2006.
105. Labrie F, Luu-The V, Belanger A, Lin SX, Simard J, Pelletier G, Labrie C. Is dehydroepiandrosterone a hormone? J Endocrinol 187: 169-196, 2005.
106. Lamounier-Zepter V, Ehrhart-Bornstein M. Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep 8: 30-34, 2006.
107. Lehoux JG, Bird IM, Rainey WE, Tremblay A, Ducharme L. Both low sodium and high potassium intake increase the level of adrenal angiotensin-II receptor type 1, but not that of adrenocorticotropin receptor. Endocrinology 134: 776-782, 1994.
108. Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 18: 121-128, 2005.
109. Lelliott C, Vidal-Puig AJ. Lipotoxicity, an imbalance between lipogenesis de novo and fatty acid oxidation. Int J Obes Relat Metab Disord 28, Suppl 4: S22-S28, 2004.
110. Lephart ED, Simpson ER, Trzeciak WH. Rat adrenal 5 alpha-reductase mRNA content and enzyme activity are sex hormone dependent. J Mol Endocrinol 6: 163-170, 1991.
111. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229, 2002.
112. Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, Lutfy K, Friedman TC. Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147: 5061-5068, 2006.
113. Livingstone DE, McInnes KJ, Walker BR, Andrew R. Increased A-ring reduction of glucocorticoids in obese Zucker rats: effects of insulin sensitization. Obes Res 13: 1523-1526, 2005.
114. Lopez-Miranda J, Perez-Martinez P, Marin C, Fuentes F, Delgado J, Perez-Jimenez F. Dietary fat, genes and insulin sensitivity. J Mol Med 85: 209-222, 2007.
115. Lu H, Boustany-Kari CM, Daugherty A, Cassis LA. Angiotensin II increases adipose angiotensinogen expression. Am J Physiol Endocrinol Metab 292: E1280-E1287, 2007.
116. Luu-The V, Pelletier G, Labrie F. Quantitative appreciation of steroidogenic gene expression in mouse tissues: new roles for type 2 5alpha-reductase, 20alpha-hydroxysteroid dehydrogenase and estrogen sulfotransferase. J Steroid Biochem Mol Biol 93: 269-276, 2005.
117. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268: 1612-1623, 1994.
118. Mai K, Bobbert T, Kullmann V, Andres J, Rochlitz H, Osterhoff M, Weickert MO, Bahr V, Mohlig M, Pfeiffer AF, Diederich S, Spranger J. Free fatty acids increase androgen precursors in vivo. J Clin Endocrinol Metab 91: 1501-1507, 2006.
119. Malendowicz LK. Effects of long-term steroid suppression on rat adrenal 5 alpha-reductase and 11 beta-hydroxylase activities and corticosterone production in vitro. Endokrinologie 80: 304-310, 1982.
120. Mallow H, Trindl A, Loffler G. Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes. Horm Metab Res 32: 500-503, 2000.
121. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91: 3171-3180, 2006.
122. Mazzocchi G, Malendowicz LK, Rebuffat P, Robba C, Gottardo G, Nussdorfer GG. Short- and long-term effects of ACTH on the adrenal zona glomerulosa of the rat. A coupled stereological and enzymological study. Cell Tissue Res 243: 303-310, 1986.
123. Mazzocchi G, Rossi GP, Neri G, Malendowicz LK, Albertin G, Nussdorfer GG. 11Beta-hydroxysteroid dehydrogenase expression and activity in the human adrenal cortex. FASEB J 12: 1533-1539, 1998.
124. McEwan PE, Vinson GP, Kenyon CJ. Control of adrenal cell proliferation by AT1 receptors in response to angiotensin II and low-sodium diet. Am J Physiol Endocrinol Metab 276: E303-E309, 1999.
125. McInnes KJ, Kenyon CJ, Chapman KE, Livingstone DE, Macdonald LJ, Walker BR, Andrew R. 5Alpha-reduced glucocorticoids, novel endogenous activators of the glucocorticoid receptor. J Biol Chem 279: 22908-22912, 2004.
126. Michailidou Z, Jensen MD, Dumesic DA, Chapman KE, Seckl JR, Walker BR, Morton NM. Omental 11beta-hydroxysteroid dehydrogenase 1 correlates with fat cell size independently of obesity. Obesity (Silver Spring) 15: 1155-1163, 2007.
127. Molta L, Schwartz U. Gonadal and adrenal androgen secretion in hirsute females. Clin Endocrinol Metab 15: 229-245, 1986.
128. Morita K, Kuwada A, Fujihara H, Morita Y, Sei H. Changes in the expression of steroid metabolism-related genes in rat adrenal glands during selective REM sleep deprivation. Life Sci 72: 1973-1982, 2003.
129. Morton NM, Densmore V, Wamil M, Ramage L, Nichol K, Bunger L, Seckl JR, Kenyon CJ. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action. Diabetes 54: 3371-3378, 2005.
130. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53: 931-938, 2004.
131. Morton NM, Ramage L, Seckl JR. Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type 1 by high-fat feeding in mice: a potential adaptive mechanism counteracting metabolic disease. Endocrinology 145: 2707-2712, 2004.
132. Mulrow PJ. Angiotensin II and aldosterone regulation. Regul Pept 80: 27-32, 1999.
133. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, Fujita T. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17: 3438-3446, 2006.
134. Nilsson M, Stulnig TM, Lin CY, Yeo AL, Nowotny P, Liu ET, Steffensen KR. Liver X receptors regulate adrenal steroidogenesis and hypothalamic-pituitary-adrenal feedback. Mol Endocrinol 21: 126-137, 2007.
135. Oishi Y, Ozono R, Yano Y, Teranishi Y, Akishita M, Horiuchi M, Oshima T, Kambe M. Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 41: 814-818, 2003.
136. Okada K, Hirano T, Ran J, Adachi M. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 27: 293-299, 2004.
137. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278: 135-138, 1997.
138. Otis M, Campbell S, Payet MD, Gallo-Payet N. The growth-promoting effects of angiotensin II in adrenal glomerulosa cells: an interactive tale. Mol Cell Endocrinol 273: 1-5, 2007.
139. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100, 2006.
140. Pasquali R. Obesity and androgens: facts and perspectives. Fertil Steril 85: 1319-1340, 2006.
141. Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann NY Acad Sci 1092: 158-174, 2006.
142. Paust HJ, Loeper S, Else T, Bamberger AM, Papadopoulos G, Pankoke D, Saeger W, Bamberger CM. Expression of the glucocorticoid receptor in the human adrenal cortex. Exp Clin Endocrinol Diabetes 114: 6-10, 2006.
143. Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator- activated receptor-gamma. Int J Biochem Cell Biol 38: 766-781, 2006.
144. Petruzzelli M, Lo Sasso G, Portincasa P, Palasciano G, Moschetta A. Targeting the liver in the metabolic syndrome: evidence from animal models. Curr Pharm Des 13: 2199-2207, 2007.
145. Phillipov G, Palermo M, Shackleton CH. Apparent cortisone reductase deficiency: a unique form of hypercortisolism. J Clin Endocrinol Metab 81: 3855-3860, 1996.
146. Phillips C, Lopez-Miranda J, Perez-Jimenez F, McManus R, Roche HM. Genetic and nutrient determinants of the metabolic syndrome. Curr Opin Cardiol 21: 185-193, 2006.
147. Piltonen T, Koivunen R, Morin-Papunen L, Ruokonen A, Huhtaniemi IT, Tapanainen JS. Ovarian and adrenal steroid production: regulatory role of LH/HCG. Hum Reprod 17: 620-624, 2002.
148. Pitts GC, Bull LS. Exercise, dietary obesity, and growth in the rat. Am J Physiol Regul Integr Comp Physiol 232: R38-R44, 1977.
149. Plante GE. Sleep and vascular disorders. Metabolism 55: S45-S49, 2006.
150. Pralong FP, Roduit R, Waeber G, Castillo E, Mosimann F, Thorens B, Gaillard RC. Leptin inhibits directly glucocorticoid secretion by normal human and rat adrenal gland. Endocrinology 139: 4264-4268, 1998.
151. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab 292: E654-E667, 2007.
152. Rainey WE. Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Mol Cell Endocrinol 151: 151-160, 1999.
153. Rainey WE, Saner K, Schimmer BP. Adrenocortical cell lines. Mol Cell Endocrinol 228: 23-38, 2004.
154. Ran J, Hirano T, Adachi M. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 287: E227-E232, 2004.
155. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism 55: 478-488, 2006.
156. Romualdi D, Giuliani M, Draisci G, Costantini B, Cristello F, Lanzone A, Guido M. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 88: 131-138, 2007.
157. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 83: 1853-1859, 1998.
158. Salehi M, Ferenczi A, Zumoff B. Obesity and cortisol status. Horm Metab Res 37: 193-197, 2005.
159. Sarel I, Widmaier EP. Stimulation of steroidogenesis in cultured rat adrenocortical cells by unsaturated fatty acids. Am J Physiol Regul Integr Comp Physiol 268: R1484-R1490, 1995.
160. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 287: H435-H446, 2004.
161. Schling P. Expression of angiotensin II receptors type 1 and type 2 in human preadipose cells during differentiation. Horm Metab Res 34: 709-715, 2002.
162. Schoneveld OJ, Gaemers IC, Lamers WH. Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 1680: 114-128, 2004.
163. Seckl JR, Walker BR. Minireview. 11Beta-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142: 1371-1376, 2001.
164. Seeley RJ, Drazen DL, Clegg DJ. The critical role of the melanocortin system in the control of energy balance. Annu Rev Nutr 24: 133-149, 2004.
165. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40: 609-611, 2002.
166. Siragy HM, Xue C, Abadir P, Carey RM. Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation. Hypertension 45: 133-137, 2005.
167. Skurk T, van Harmelen V, Blum WF, Hauner H. Angiotensin II promotes leptin production in cultured human fat cells by an ERK1/2-dependent pathway. Obes Res 13: 969-973, 2005.
168. Smith AG, Muscat GE. Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease. Int J Biochem Cell Biol 37: 2047-2063, 2005.
169. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol 99: 2008-2019, 2005.
170. Spinazzi R, Andreis PG, Nussdorfer GG. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review). Int J Mol Med 15: 3-13, 2005.
171. Stewart PM. Mineralocorticoid hypertension. Lancet 353: 1341-1347, 1999.
172. Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 Alpha-reductase activity in polycystic ovary syndrome. Lancet 335: 431-433, 1990.
173. Stulnig TM, Oppermann U, Steffensen KR, Schuster GU, Gustafsson JA. Liver X receptors downregulate 11beta-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes 51: 2426-2433, 2002.
174. Suchecki D, Lobo LL, Hipolide DC, Tufik S. Increased ACTH and corticosterone secretion induced by different methods of paradoxical sleep deprivation. J Sleep Res 7: 276-281, 1998.
175. Sukhija R, Kakar P, Mehta V, Mehta JL. Enhanced 11beta-hydroxysteroid dehydrogenase activity, the metabolic syndrome, and systemic hypertension. Am J Cardiol 98: 544-548, 2006.
176. Svartberg J. Epidemiology: testosterone and the metabolic syndrome. Int J Impot Res 19: 124-128, 2007.
177. Takeuchi S, Takahashi S. A possible involvement of melanocortin 3 receptor in the regulation of adrenal gland function in the chicken. Biochim Biophys Acta 1448: 512-518, 1999.
178. Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol 151: 1-14, 2004.
179. Thakur V, Richards R, Reisin E. Obesity, hypertension, and the heart. Am J Med Sci 321: 242-248, 2001.
180. Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul Pharmacol 45: 19-28, 2006.
181. Townsend RR. The effects of angiotensin-II on lipolysis in humans. Metabolism 50: 468-472, 2001.
182. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab 88: 5907-5913, 2003.
183. Van Cauter E, Holmback U, Knutson K, Leproult R, Miller A, Nedeltcheva A, Pannain S, Penev P, Tasali E, Spiegel K. Impact of sleep and sleep loss on neuroendocrine and metabolic function. Horm Res 67, Suppl 1: 2-9, 2007.
184. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev 18: 716-738, 1997.
185. van Harmelen V, Elizalde M, Ariapart P, Bergstedt-Lindqvist S, Reynisdottir S, Hoffstedt J, Lundkvist I, Bringman S, Arner P. The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int J Obes Relat Metab Disord 24: 673-678, 2000.
186. Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. Jama 292: 2243-2248, 2004.
187. Vinson GP. Angiotensin II, corticosteroids, type II diabetes and the metabolic syndrome. Med Hypotheses 68: 1200-1207, 2007.
188. Volpe M, Musumeci B, De Paolis P, Savoia C, Morganti A. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 21: 1429-1443, 2003.
189. Wade MR, Degroot A, Nomikos GG. Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents. Eur J Pharmacol 551: 162-167, 2006.
190. Walker BR. Cortisol - cause and cure for metabolic syndrome? Diabet Med 23: 1281-1288, 2006.
191. Walker BR. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning. Proc Nutr Soc 66: 1-8, 2007.
192. Walker BR, Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann NY Acad Sci 1083: 165-184, 2006.
193. Walker CD, Salzmann C, Long H, Otis M, Roberge C, Gallo-Payet N. Direct inhibitory effects of leptin on the neonatal adrenal and potential consequences for brain glucocorticoid feedback. Endocr Res 30: 837-844, 2004.
194. Warne JP, Dallman MF. Stress, diet and abdominal obesity: Y? Nat Med 13: 781-783, 2007.
195. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD. Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51: 1066-1075, 2002.
196. Widdop RE, Jones ES, Hannan RE, Gaspari TA. Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 140: 809-824, 2003.
197. Widmaier EP, Rosen K, Abbott B. Free fatty acids activate the hypothalamic-pituitary-adrenocortical axis in rats. Endocrinology 131: 2313-2318, 1992.
198. Willoughby KA, Moore SF, Martin BR, Ellis EF. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282: 243-247, 1997.
199. Wu XK, Zhou SY, Sallinen K, Pollanen P, Erkkola R. Ovarian-adrenal cross-talk in polycystic ovary syndrome: evidence from wedge resection. Eur J Endocrinol 143: 383-388, 2000.
200. Young M, Funder JW. Aldosterone and the heart. Trends Endocrinol Metab 11: 224-226, 2000.
201. Yvan-Charvet L, Even P, Bloch-Faure M, Guerre-Millo M, Moustaid-Moussa N, Ferre P, Quignard-Boulange A. Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54: 991-999, 2005.
202. Yvan-Charvet L, Even P, Lamande N, Ferre P, Quignard-Boulange A. Prevention of adipose tissue depletion during food deprivation in angiotensin type 2 receptor-deficient mice. Endocrinology 147: 5078-5086, 2006.
203. Zakrzewska KE, Cusin I, Sainsbury A, Rohner-Jeanrenaud F, Jeanrenaud B. Glucocorticoids as counterregulatory hormones of leptin: toward an understanding of leptin resistance. Diabetes 46: 717-719, 1997.
204. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614, 2006.
205. Zhang F, Lavan BE, Gregoire FM. Selective modulators of PPARgamma activity: molecular aspects related to obesity and side-effects. PPAR Res 2007: 32696, 2007.
206. Zhao Y, Foryst-Ludwig A, Bruemmer D, Culman J, Bader M, Unger T, Kintscher U. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J Neurochem 94: 1395-1401, 2005.
207. Zorad S, Dou JT, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur J Pharmacol 552: 112-122, 2006.